Abstract:Objective To investigate the clinical significance of pyrosequencing assay for determining K-ras mutations in exon 2 codons 12 and 13 in clinical colorectal cancer tissues.Methods Genomic DNA,extracted from K-ras mutant cell lines SW480 (homozygous,c.35G ＞ T), DLD-1 (heterozygous,c.38G ＞ A) and wild-type HT-29,was first used as the sequencing template respectively to test the accuracy of pyrosequencing methodology.The SW480 and DLD-1 DNA was separately mixed with wild-type HT-29 DNA in proportions of 2％,3％,5％,10％,20％,30％ and 50％,the sensitivity for mutation detection was measured separately by pyrosequencing assay and directed Sanger DNA sequencing in the serial DNA mixture samples.The pyrosequencing assay results were compared with the corresponding Sanger sequencing and the datas were analysized by Fisher exact test.Pyrosequencing analysis was then performed for screening K-ras exon 2 mutations at codons 12 and 13 on DNA isolated from a panel of 30 colorectal cancer samples derived from clinical formalin-fixed and paraffin embedded (FFPE)tissues.Results Cancer cell lines with known K-ras mutations ( SW480 and DLD-1 ) were readily detectable by pyrosequencing-based analysis.When the proportions of mutant colorectal cancer cell line DNA were 5％ and 10％ content,the mutation rates of K-ras gene detected by conventional Sanger DNA sequencing were 33.3％ (4/12) and 58.3％ (7/12) respectively,whereas the mutation rates detected by pyrosequencingbased assay were 91.7％ (11/12) and 100％ (12/12) respectively,there were significant differences between those two sequencing methodology ( P ＜0.05).Furthermore,we found 10 patients with K-ras exon 2 point mutations at codons 12 and 13 by pyrosequencing-based assay from 30 colorectal cancer FFPE tissues,the point mutation rate was 33.3％ (10/30) and all of the mutations determined were heterozygous.The codon 12 was most frequently affected [30％ (9/30)].Mutations with the highest frequency were G ＞ A transitions [ 50％ ( 5/10 ) ],followed by G ＞ T transversions [ 30％ ( 3/10 ) ].Conclusion The pyrosequencing assay provides an accurate and sensitive method for mutation screening of K-ras exon 2 codons 12 and 13 in routine diagnostic specimens,thereby allowing the selection of the cancer treatment in clinical individualized practice.

A Novel Point Mutation of K-ras Gene Coexisted with Codon 12 Mutation

Values of Mutations of K-ras Oncogene at Codon 12 in Detection of Pancreatic Cancer: 15-Year Experience

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients with Metastatic Colorectal Cancer.

[K-Ras Gene Mutation in Colorectal Cancer and Its Clinicopathologic Significance].

Relationship Between K-ras Mutational Status and Clinical Pathological Characteristics in Colorectal Cancer

Genotyping of K-ras Exon 2 Codons 12 and 13 Mutations in Colorectal Cancer by Pyrosequencing

Identification of K-RAS Codon 12, 13 and B-RAF V600E Mutation in Different Stages of Colorectal Cancer Tumorigenesis with High-Resolution Melting Analysis

Detection of K-ras Mutation in Colorectal Cancer and Its Clinicopathological Significance

Mutations of K-ras gene in lung cancer

Detection of K-ras mutation in advanced colorectal carcinoma by Pyrosequencing

The Value of K-ras Gene Point Mutation in the Diagnosis of Pancreatic Adenocarcinoma

The relationship between K-ras gene mutation with clinicopathological and prognosis in gallbladder carcinoma

Correlation analysis between K-ras gene mutation expression and colorectal cancer

[Significance of K-ras Detection in Colorectal Cancer].

K-ras gene mutation status in 454 Chinese patients with colorectal cancer

Establishment of pyrosequencing method for detection of k-ras mutation

Detection of K-ras Gene Point Mutation and Its Style at Codon 12 in Human Pancreatic Cancer Cell Line Patu 8988 by PCR-SSP and Sequence Analysis

Detection of KRAS,NRAS and BRAF Gene Mutations in Colorectal Carcinoma

Mutations in Epidermal Growth Factor Receptor and K-ras in Chinese Patients with Colorectal Cancer

Mutations of K-ras oncogene in primary colorectal tumors, related liver metastases and portal vein blood of patients with colorectal cancer

Not All Mutations of KRAS Predict Poor Prognosis in Patients with Colorectal Cancer.